Investor Relations

Investor Search

Entire IR Site
Press Releases Only
Filings Only
Email pagePDF viewPrint viewEmail AlertRSS FeedsTearsheetMobile IR SiteSocial Media Sharing

Press Releases


Notify me when new press releases are posted to this site .
Press Releases 
11/08/2012Repligen Reports Third Quarter 2012 Financial Results
11/07/2012Repligen CEO to Present at Upcoming Investor Conferences
10/26/2012Repligen To Report Third Quarter of 2012 Financial Results
9/21/2012Repligen Appoints Jonathan I. Lieber as CFO
8/29/2012Repligen to Present at Stifel Nicolaus Healthcare Conference 2012
8/02/2012Repligen Announces Strategic Focus on Bioprocessing Business and Reports Second Quarter 2012 Financial Results
7/24/2012Repligen To Report Second Quarter of 2012 Financial Results
7/06/2012Repligen to Present at JMP Securities Healthcare Conference 2012
6/25/2012Repligen Added to the Russell 2000 Index
6/22/2012Repligen Receives Complete Response Letter from FDA for RG1068 NDA
5/30/2012Repligen to Present at Jefferies 2012 Global Healthcare Conference
5/07/2012Repligen Announces Support of Amended Stockholder Proposal
5/03/2012Repligen Reports First Quarter 2012 Financial Results
4/30/2012Repligen Announces Conference Call to Report First Quarter of 2012 Financial Results
4/26/2012Repligen Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee Meeting
4/25/2012Repligen Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy
4/11/2012Michael A. Griffith Appointed to Repligen Board of Directors
3/23/2012Repligen Announces FDA Advisory Committee Date for SecreFlo™ NDA
3/16/2012Repligen Reports Financial Results for the Quarter and Nine-Month Fiscal Year Ended December 31, 2011
3/15/2012Repligen Initiates Phase 1 Clinical Trial of RG2833 in Patients with Friedreich’s Ataxia
Click the link to the right to download: Adobe Acrobat
 Source: SNL Financial LC
Rows 41 through 60 of 157 1 2 3 4 5 6 7 8

Copyright 2015, © SNL Financial LC  Terms of Use